I find your claim hard to believe, especially given your posting history and alias. I’m unsure how NP mentioning data before submission has anything to do with nullifying the peer review or publication process. Many COVID related articles in the NEJM were discussed before NEJM published them. Additionally, the ENTIRE article is published online, for the world to review and peers to review, prior to submission to a journal. So again, NP mentioning the findings on a paid interview doesn’t seem to meet criteria for rejection.

I’ll await feedback from CDiddy or another legitimate investor to confirm whether your statement is true as anything is possible at this point.